Abstract:Objective: To investigate the impact of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD). Methods: A retrospective cohort study was performed to include 178 patients with Ⅲ-Ⅳ NSCLC complicated with COPD who received at least 2 times of immunotherapy in Xinqiao Hospital of the Army Medical University from January 2019 to August 2021. Baseline peripheral blood inflammatory indicators such as interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α) were collected within 2 weeks before the first treatment, with the last one being on or before February 7, 2022. X-tile software was used to determine the optimal cut-off value of peripheral blood inflammatory indicators. The Cox multivariate regression models were used to analyze the factors affecting progression free survival (PFS) and overall survival (OS). Results: Among the 178 patients, there were 174 males (97.8%) and 4 females (2.2%); the age ranged from 42 to 86 (64.3±8.3) years old.There were 30 cases (16.9%) of immunotherapy monotherapy, 114 cases (64.0%) of immunotherapy combined with chemotherapy, 21 cases (11.8%) of immunotherapy combined with antivascular therapy, and 13 cases (7.3%) of immunotherapy combined with radiotherapy. The median follow-up period was 14.5 months (95%CI: 13.6-15.3 months). The objective response rate (ORR) and disease control rate (DCR) were 44.9% (80/178) and 90.4% (161/178) for the whole group, the median PFS was 14.6 months (95%CI: 11.6-17.6 months), and the median OS was 25.7 months (95%CI: 18.0-33.4 months). The results of Cox multivariate analysis showed that IL-6>9.9 ng/L (HR=5.885, 95%CI: 2.558-13.543, P<0.01), TNF-α>8.8 ng/L (HR=3.213, 95%CI: 1.468-7.032, P=0.003), IL-8>202 ng/L (HR=2.614, 95%CI: 1.054-6.482, P=0.038), systemic immune inflammatory index (SII)>2 003.95 (HR=2.976, 95%CI: 1.647-5.379, P<0.001) were risk factors for PFS, and advanced lung cancer inflammation index (ALI)>171.15 was protective factor for PFS (HR=0.545, 95%CI: 0.344-0.863, P=0.010). IL-6>9.9 ng/L(HR=6.124, 95%CI: 1.950-19.228, P<0.002), lactate dehydrogenase (LDH)>190.7 U/L (HR=2.776, 95%CI: 1.020-7.556, P=0.046), SII>2 003.95 (HR=4.521, 95%CI: 2.241-9.120, P<0.001) were risk factors for OS, and ALI>171.15 was a protective factor for OS (HR=0.434, 95%CI: 0.243-0.778, P=0.005). Conclusion: Baseline high levels of IL-6, TNF-α, IL-8, SII, LDH, and low levels of ALI are risk factors for poor prognosis in patients with advanced NSCLC-COPD receiving immunotherapy.

A Comparative Study on Inflammatory Factors and Immune Functions of Lung Cancer and Pulmonary Ground-Glass Attenuation.

Combining High-Resolution CT Parameters and Inflammatory Markers to Predict Spread Through Air Spaces in Lung Cancer

Comparative Study on Cytokines in Peripheral Blood and Lung Function of Idiopathic Interstitial Pneumonia Patients with Different Imaging

The Microbiome of Lower Respiratory Tract and Tumor Tissue in Lung Cancer Manifested As Radiological Ground-Glass Opacity

Differential Diagnosis of Solitary Pulmonary Inflammatory Lesions and Peripheral Lung Cancers with Contrast-enhanced Computed Tomography

Change of Serum Inflammatory Cytokines Levels in Patients With Chronic Obstructive Pulmonary Disease, Pneumonia and Lung Cancer

Characterization of blood inflammatory markers in patients with non-small cell lung cancer

Auxiliary Diagnostic Value Of Gamma Delta T Cell, Il-17, And Ifn-Y Levels In Peripheral Blood And Bronchoalveolar Lavage Fluid For Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease

Clinical Evaluation of Lung Function in 74 Patients with Inflammatory Bowel Disease

Differences in Serum Cytokine Levels Distinguish Between Clinically Noninvasive Lung Adenocarcinoma and Invasive Lung Adenocarcinoma: A Cross‐sectional Study

[Comparison of Enhanced Thin CT Sections with Pathologic Findings in Pulmonary Carcinoma, Inflammatory, Pseudo-Tumor and Pulmonary Tuberculoma].

Comparison of characteristics of connective tissue disease-associated interstitial lung diseases and ;idiopathic pulmonary fibrosis

Comparative Study of Focal Pulmonary Ground Glass Nodule Between Findings of High Resolution CT and Pathology Classiifcation of IASLC/ATS/ERS

Analysis of Lung Ground-glass Nodules From the Perspective of Inflammation-to-cancer Transition Based on Il-6 Level and Clinical Features

The Changes of Peripheral Blood Lymphocyte Subsets and Cytokine in Patients with Lung Adenocarcinoma at Different Stages

Contrast analysis on spiral CT and pathological findings of sub-centimetre pulmonary ground glass nodules

Changes of CD4+CD25+CD127-regulatory T Cells Level and Clinical Significance in the Peripheral Blood of Patients with Lung Cancer

[Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease]

Comparison of characteristics of connective tissue disease-associated pulmonary fibrosis, undifferentiated connective tissue disease-associated pulmonary fibrosis,and idiopathic pulmonary fibrosis

Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity